COVID-19 vaccines versus pediatric hospitalization
暂无分享,去创建一个
H. So | W. Wong | Derek Lee | Y. Lau | D. Leung | J. S. Rosa Duque | K. M. Yip | J. R. Rosa Duque
[1] H. So,et al. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong , 2023, Communications Medicine.
[2] N. Pearce,et al. Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period , 2022, Nature Communications.
[3] A. Cook,et al. Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.
[4] A. Palamara,et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022 , 2022, The Lancet.
[5] M. Hernán,et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age , 2022, The New England journal of medicine.
[6] M. Peiris,et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents , 2022, Nature Communications.
[7] J. Chan,et al. Severity of SARS-CoV-2 Omicron BA.2 infection in unvaccinated hospitalized children: comparison to influenza and parainfluenza infections , 2022, Emerging microbes & infections.
[8] E. Undurraga,et al. Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile , 2022, Nature Medicine.
[9] L. Abu-Raddad,et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization , 2022, Vaccine.
[10] E. Estenssoro,et al. Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.
[11] Manish M Patel,et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents , 2022, The New England journal of medicine.
[12] Andrew L. Phillips,et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[13] S. Zeger,et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.
[14] M. Lipsitch,et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study , 2021, The Lancet Infectious Diseases.
[15] John Adams. Assessing , 2020, Transport Planning.